|
1
|
Cancer statistics. JAMA. 310:9822013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fowler W and Mutch D: Management of
endometrial cancer. Womens Health (Lond Engl). 4:479–489. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Millimaggi D, Mari M, D'Ascenzo S, et al:
Tumor vesicle-associated CD147 modulates the angiogenic capability
of endothelial cells. Neoplasia. 9:349–357. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sidhu SS, Mengistab AT, Tauscher AN,
LaVail J and Basbaum C: The microvesicle as a vehicle for EMMPRIN
in tumor-stromal interactions. Oncogene. 23:956–963. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Garg K, Leitao MM Jr, Wynveen CA, et al:
p53 overexpression in morphologically ambiguous endometrial
carcinomas correlates with adverse clinical outcomes. Mod Pathol.
23:80–92. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Davidson B, Goldberg I, Berner A, et al:
EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel
marker of poor outcome in serous ovarian carcinoma. Clin Exp
Metastasis. 20:161–169. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsai WC, Chao YC, Sheu LF, et al: EMMPRIN
and fascin overexpression associated with clinicopathologic
parameters of pancreatobiliary adenocarcinoma in Chinese people.
APMIS. 115:929–938. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zheng HC, Takahashi H, Murai Y, et al:
Upregulated EMMPRIN/CD147 might contribute to growth and
angiogenesis of gastric carcinoma: a good marker for local invasion
and prognosis. Br J Cancer. 95:1371–1378. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhong WD, Liang YX, Lin SX, et al:
Expression of CD147 is associated with prostate cancer progression.
Int J Cancer. 130:300–308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu W, Liu J, Xiong X, et al: Expression of
MMP9 and CD147 in invasive squamous cell carcinoma of the uterine
cervix and their implication. Pathol Res Pract. 205:709–715. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Klein CA, Seidl S, Petat-Dutter K, et al:
Combined transcriptome and genome analysis of single
micrometastatic cells. Nat Biotechnol. 20:387–392. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu W, Wang R, Liu H, et al: Prediction of
prognosis in gallbladder carcinoma by CD147 and MMP-2
immunohistochemistry. Med Oncol. 26:117–123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Morris PC, Anderson JR, Anderson B and
Buller RE: Steroid hormone receptor content and lymph node status
in endometrial cancer. Gynecol Oncol. 56:406–411. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kleine W, Maier T, Geyer H and Pfleiderer
A: Estrogen and progesterone receptors in endometrial cancer and
their prognostic relevance. Gynecol Oncol. 38:59–65. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pertschuk LP, Masood S, Simone J, et al:
Estrogen receptor immunocytochemistry in endometrial carcinoma: a
prognostic marker for survival. Gynecol Oncol. 63:28–33. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deen S: FIGO staging of endometrial
adenocarcinoma: a critical review and proposal. Int J Gynecol
Pathol. 28:477–478. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Horn LC, Schmidt D, Fathke C and Ulrich U:
Mitglieder der Organgruppe Uterus der AGO: New FIGO staging for
uterine sarcomas. Pathologe. 30:302–303. 2009.(In German).
PubMed/NCBI
|
|
18
|
Kamat AA, Fletcher M, Gruman LM, et al:
The clinical relevance of stromal matrix metalloproteinase
expression in ovarian cancer. Clin Cancer Res. 12:1707–1714. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gou XX, Jin F, Chen HX, Wu WL, Chen L and
Zeng Y: Expressions of CD147, MMP-2 and MMP-9 in laryngeal
carcinoma and clinical significance. Zhonghua Yi Xue Za Zhi.
90:1264–1267. 2010.(In Chinese). PubMed/NCBI
|
|
20
|
Wang S, Li B, Wang S, Li Y and Li J:
Expression and clinical significance of CD147 and MMP-2 in squamous
cell carcinoma and adenocarcinoma of the lungs. Zhongguo Fei Ai Za
Zhi. 14:710–714. 2011.(In Chinese). PubMed/NCBI
|
|
21
|
Tan H, Ye K, Wang Z and Tang H:
Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2
expression in differentiated thyroid carcinoma. Jpn J Clin Oncol.
38:528–533. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kanekura T and Chen X: CD147/basigin
promotes progression of malignant melanoma and other cancers. J
Dermatol Sci. 57:149–154. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xue YJ, Lu Q and Sun ZX: CD147
overexpression is a prognostic factor and a potential therapeutic
target in bladder cancer. Med Oncol. 28:1363–1372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rosenthal EL, Shreenivas S, Peters GE, et
al: Expression of extracellular matrix metalloprotease inducer in
laryngeal squamous cell carcinoma. Laryngoscope. 113:1406–1410.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tan H, Ye K, Wang Z and Tang H: CD147
expression as a significant prognostic factor in differentiated
thyroid carcinoma. Transl Res. 152:143–149. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao L, Yu N, Guo T, et al: Tissue
biomarkers for prognosis of prostate cancer: a systematic review
and meta-analysis. Cancer Epidemiol Biomarkers Prev. 23:1047–1054.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang JM, Xu Z, Wu H, Zhu H, Wu X and Hait
WN: Overexpression of extracellular matrix metalloproteinase
inducer in multidrug resistant cancer cells. Mol Cancer Res.
1:420–427. 2003.PubMed/NCBI
|
|
28
|
Liang Q, Xiong H, Gao G, et al: Inhibition
of basigin expression in glioblastoma cell line via antisense RNA
reduces tumor cell invasion and angiogenesis. Cancer Biol Ther.
4:759–762. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang Y, Nakada MT, Rafferty P, et al:
Regulation of vascular endothelial growth factor expression by
EMMPRIN via the PI3K-Akt signaling pathway. Mol Cancer Res.
4:371–377. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yan L, Zucker S and Toole BP: Roles of the
multifunctional glycoprotein, emmprin (basigin; CD147), in tumour
progression. Thromb Haemost. 93:199–204. 2005.PubMed/NCBI
|
|
31
|
Aristizabal P, Graesslin O, Barranger E,
et al: A suggested modification to FIGO stage I endometrial cancer.
Gynecol Oncol. 133:192–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aliagas E, Vidal A, Texidó L, et al: High
expression of ecto-nucleotidases CD39 and CD73 in human endometrial
tumors. Mediators Inflamm. 2014:5090272014.PubMed/NCBI
|
|
33
|
Nakamura K, Kodama J, Hongo A and
Hiramatsu Y: Role of emmprin in endometrial cancer. BMC Cancer.
12:1912012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ueda K, Yamada K, Urashima M, et al:
Association of extracellular matrix metalloproteinase inducer in
endometrial carcinoma with patient outcomes and clinicopathogenesis
using monoclonal antibody 12C3. Oncol Rep. 17:731–735.
2007.PubMed/NCBI
|
|
35
|
Morris PC, Anderson JR, Anderson B and
Buller RE: Steroid hormone receptor content and lymph node status
in endometrial cancer. Gynecol Oncol. 56:406–411. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Thigpen JT, Brady MF, Alvarez RD, et al:
Oral medroxyprogesterone acetate in the treatment of advanced or
recurrent endometrial carcinoma: a dose-response study by the
Gynecologic Oncology Group. J Clin Oncol. 17:1736–1744.
1999.PubMed/NCBI
|
